Article Sidebar

PDF (Tiếng Việt)
Published: 2023-01-30
Abstract Views: 246
Views PDF (Tiếng Việt): 321
DOI: https://doi.org/10.52852/tcncyh.v160i12V2.1287
Issue
Vol. 160 No. 12V2 (2022)
Section
Các bài báo
How to Cite
Đức, L. T. ., & Lập, B. T. . (2023). 23. Clinical, subclinical characteristics and survival time of testicular cancer at K Hospital. Journal of Medical Research, 160(12V2), 190-197. https://doi.org/10.52852/tcncyh.v160i12V2.1287

23. Clinical, subclinical characteristics and survival time of testicular cancer at K Hospital

Le Thanh Duc, Bui Thanh Lap

Main Article Content

Abstract

This is a retrospective, descriptive study with longitudinal follow-up aimed to describe the clinical and subclinical characteristics and evaluate the survival time of patients with testicular cancer at K Hospital from January 2015 to June 2022. Among the 61 patients in the study, the average age was 31.0 years old. The proportions of patients with stage I, II and III were 67.2%, 22.9% and 9.8%, respectively. Seminoma accounted for 60.7% and nonseminoma accounted for 39.3%. The average disease-free survival time was 68.9 months. The 5-year disease-free survival rate was 79.9%. The average overall survival was 74.1 months. The overall 5-year survival rate was 87.6%. Compared with the group of nonseminoma patients, patients with seminoma had siegnificantly higher 5-year disease-free survival rate (93.3% vs 57.1%; p = 0.007) and overall 5-year survival rate (96.8% vs 72.4%; p = 0.023).

Article Details

Keywords

testicular cancer, disease-free survival, overall survival

References

1. Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Cancer Netw JNCCN. 2009;7(6):672-693.
2. Bani-Hani KE, Matani YS, Bani-Hani IH. Cryptorchidism and testicular neoplasia. Saudi Med J. 2003;24:166-169 .
3. Abratt RP, Reddi VB, Sarembok LA: Testicular Cancer and Cryptorchidism. Br J Urol. 1992;70(6):656-659.
4. Giwercman A, Grinsted J, Hansen B, Jensen OM, Skakkebaek NE: Testicular Cancer risk in boys with maldescended testis. A cohort study. J Urol. 1987;138(5):1214-1216.
5. Thorup J, Mclachlan R, Cortes D, Nation TR, Balic A, Southwell BR, et al. What is new in cryptorchidism and hypospadias - a critical review on the testicular dysgenesis hypothesis. J Pediatr Surg. 2010;45:2074-2086.
6. Woodward PJ. Case 70: seminoma in an undescended testis. Radiology. 2004;231(2):388-392.
7. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: Renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93-105.
8. Cấn Xuân Hạnh: Đánh giá kết quả điều trị ung thư tinh hoàn tại Bệnh viện K từ 2005 đến 2013. Luận văn thạc sỹ. Trường Đại học Y Hà Nội; 2014.
9. Woldu SL, Bagrodia A. Update on epidemiologic considerations and treatment trends in testicular cancer. Curr Opin Urol. 2018;28(5):440-447.
10. Nguyễn Văn Nam. Đánh giá kết quả điều trị ung thư tinh hoàn tại BV Hữu Nghị Việt Đức và BV K giai đoạn 2010 - 2017. Luận văn thạc sỹ. Trường Đại học Y Hà Nội; 2018.
11. Trần Thiện Khiêm. Đánh giá kết quả sống còn trong điều trị ung thư tinh hoàn. Tạp chí Y học Tp.Hồ Chí Minh. 2022;26(1).
12. Trần Quốc Hùng. Đánh giá kết quả điều trị ung thư tinh hoàn và một số yếu tố tiên lượng các thể bệnh thường gặp (1988 - 2005). Luận án tiến sỹ y học. Học viện Quân Y; 2007.
13. Schaffar R, Pant S, Bouchardy C, Schubert H, Rapiti E. Testicular cancer in Geneva, Switzerland, 1970 - 2012: Incidence trends, survival and risk of second cancer. BMC Urol. 2019;19(1):64.